These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 38533706)
41. Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma. Kim SY; Kim SM; Lim S; Lee JY; Choi SJ; Yang SD; Yun MR; Kim CG; Gu SR; Park C; Park AY; Lim SM; Heo SG; Kim H; Cho BC Clin Cancer Res; 2021 Aug; 27(15):4397-4409. PubMed ID: 34083237 [TBL] [Abstract][Full Text] [Related]
42. Organoid technology in cancer precision medicine. Xia X; Li F; He J; Aji R; Gao D Cancer Lett; 2019 Aug; 457():20-27. PubMed ID: 31078736 [TBL] [Abstract][Full Text] [Related]
43. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response. Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064 [TBL] [Abstract][Full Text] [Related]
44. Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer. He X; Jiang Y; Zhang L; Li Y; Hu X; Hua G; Cai S; Mo S; Peng J Front Bioeng Biotechnol; 2023; 11():1190637. PubMed ID: 37284236 [No Abstract] [Full Text] [Related]
45. Antitumor effect of luteolin proven by patient-derived organoids of gastric cancer. Hao X; Zu M; Ning J; Zhou X; Gong Y; Han X; Meng Q; Li D; Ding S Phytother Res; 2023 Nov; 37(11):5315-5327. PubMed ID: 37469042 [TBL] [Abstract][Full Text] [Related]
46. Comparison of Surgical and Colonoscopy Tissue to Establish Colorectal Patient-derived Organoids. Chen H; Yang Y; Shi J; Yan T; Wang J; Yang Y; Lu Q; Feng H; Du J; Cao Z; Weygant N Curr Cancer Drug Targets; 2024; 24(5):546-555. PubMed ID: 37997804 [TBL] [Abstract][Full Text] [Related]
48. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer. Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806 [TBL] [Abstract][Full Text] [Related]
49. Patient-derived cancer organoids for drug screening: Basic technology and clinical application. Ren X; Chen W; Yang Q; Li X; Xu L J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719 [TBL] [Abstract][Full Text] [Related]
50. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544 [TBL] [Abstract][Full Text] [Related]
51. Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy. Shu D; Shen M; Li K; Han X; Li H; Tan Z; Wang Y; Peng Y; Tang Z; Qu C; Jin A; Liu S Ann Med; 2022 Dec; 54(1):2581-2597. PubMed ID: 36194178 [TBL] [Abstract][Full Text] [Related]
53. Ovarian Cancer Patient-Derived Organoids Used as a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness: A Preliminary Study. Chang YH; Wu KC; Wang KH; Ding DC Cell Transplant; 2024; 33():9636897241281869. PubMed ID: 39323050 [TBL] [Abstract][Full Text] [Related]
54. Patient-derived organoids of non-small cells lung cancer and their application for drug screening. Li YF; Gao Y; Liang BW; Cao XQ; Sun ZJ; Yu JH; Liu ZD; Han Y Neoplasma; 2020 Mar; 67(2):430-437. PubMed ID: 31973535 [TBL] [Abstract][Full Text] [Related]
56. Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation. Pasch CA; Favreau PF; Yueh AE; Babiarz CP; Gillette AA; Sharick JT; Karim MR; Nickel KP; DeZeeuw AK; Sprackling CM; Emmerich PB; DeStefanis RA; Pitera RT; Payne SN; Korkos DP; Clipson L; Walsh CM; Miller D; Carchman EH; Burkard ME; Lemmon KK; Matkowskyj KA; Newton MA; Ong IM; Bassetti MF; Kimple RJ; Skala MC; Deming DA Clin Cancer Res; 2019 Sep; 25(17):5376-5387. PubMed ID: 31175091 [TBL] [Abstract][Full Text] [Related]
57. Advances and Applications of Cancer Organoids in Drug Screening and Personalized Medicine. Yang Y; Kong Y; Cui J; Hou Y; Gu Z; Ma C Stem Cell Rev Rep; 2024 Jul; 20(5):1213-1226. PubMed ID: 38532032 [TBL] [Abstract][Full Text] [Related]
58. Application of Cancer Organoid Model for Drug Screening and Personalized Therapy. Kondo J; Inoue M Cells; 2019 May; 8(5):. PubMed ID: 31108870 [TBL] [Abstract][Full Text] [Related]
59. Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy. Driehuis E; Kolders S; Spelier S; Lõhmussaar K; Willems SM; Devriese LA; de Bree R; de Ruiter EJ; Korving J; Begthel H; van Es JH; Geurts V; He GW; van Jaarsveld RH; Oka R; Muraro MJ; Vivié J; Zandvliet MMJM; Hendrickx APA; Iakobachvili N; Sridevi P; Kranenburg O; van Boxtel R; Kops GJPL; Tuveson DA; Peters PJ; van Oudenaarden A; Clevers H Cancer Discov; 2019 Jul; 9(7):852-871. PubMed ID: 31053628 [TBL] [Abstract][Full Text] [Related]
60. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer. Shi R; Radulovich N; Ng C; Liu N; Notsuda H; Cabanero M; Martins-Filho SN; Raghavan V; Li Q; Mer AS; Rosen JC; Li M; Wang YH; Tamblyn L; Pham NA; Haibe-Kains B; Liu G; Moghal N; Tsao MS Clin Cancer Res; 2020 Mar; 26(5):1162-1174. PubMed ID: 31694835 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]